Heart Failure

Subscribe to Selected New Research on Heart Failure

31891 relevant articles (2626 outcomes, 5132 trials/studies) found for this Disease

Description: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.

Also Known As:

Congestive Heart Failure; Heart Failure, Congestive; Heart Failure, Left-Sided; Heart Failure, Right-Sided; Left-Sided Heart Failure; Myocardial Failure; Right-Sided Heart Failure; Decompensation, Heart; Heart Failure, Left Sided; Heart Failure, Right Sided; Left Sided Heart Failure; Right Sided Heart Failure; Cardiac Failure; Heart Decompensation

Relationship Network

Disease Context: Research Results

Cardiovascular Diseases: 18509

Heart Diseases: 12346

Heart Failure: 31891

Systolic Heart Failure: 193

Diastolic Heart Failure: 121

Cardiac Edema: 90

Paroxysmal Dyspnea: 11

Related Diseases

1.	Hypertension (High Blood Pressure)
2.	Myocardial Infarction
3.	Heart Failure
4.	Left Ventricular Dysfunction
5.	Cardiomyopathies (Cardiomyopathy)

Experts

1.	Gheorghiade, Mihai: 50 articles (10/2008 - 01/2002)
2.	Swedberg, Karl: 49 articles (10/2008 - 04/2002)
3.	McMurray, John J V: 41 articles (10/2008 - 01/2002)
4.	Burnett, John C: 38 articles (06/2008 - 02/2002)
5.	Anker, Stefan D: 38 articles (05/2008 - 04/2002)
6.	van Veldhuisen, Dirk J: 37 articles (10/2008 - 03/2002)
7.	Krum, Henry: 35 articles (10/2008 - 08/2002)
8.	Cohn, Jay N: 35 articles (09/2008 - 04/2002)
9.	Abraham, William T: 35 articles (07/2008 - 07/2002)
10.	Cleland, John G F: 34 articles (08/2008 - 05/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Heart Failure:

1.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 11/01/2000 - "Although most primary care physicians stated they prescribe ACE inhibitors in heart failure, this was for only 47-62% of patients, and at doses below those identified as effective in trials" 10/02/1990 - "An understanding of the renal effects of ACE inhibitors permits their safe and effective use in most patients with congestive heart failure." 02/01/2000 - "BACKGROUND: Although angiotensin-converting enzyme inhibitors are recommended as first line therapy in patients with chronic heart failure, the target doses proven to be effective in major morbidity and mortality trials (e.g" 12/01/1997 - "BACKGROUND: Several studies document an underuse of angiotensin-converting enzyme inhibitors (ACEIs) in heart failure (HF) patients, despite their proven efficacy and good tolerability" 12/01/2002 - "Given the dramatic decline in quality of life with heart failure, this end-point should be a much more important target for healthcare interventions, especially treatments such as ACE inhibitors and beta-blockers that are shown to improve quality of life." Order ALL the reference details at left...
2.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 12/01/2002 - "This is important since interventions that have been shown to improve mortality in patients with heart failure such as angiotensin converting enzyme inhibitor and beta-blockers had a favorable impact on the LV remodeling process" 03/28/2008 - "OBJECTIVE: Angiotensin-converting enzyme inhibitor (ACEI) is beneficial in patients with congestive heart failure (CHF)" 01/01/2002 - "The overall high rates of adherence to angiotensin-converting enzyme inhibitor therapy observed among heart failure clinic patients is consistent with research that shows improved outcomes for patients managed in heart failure clinics" 08/01/2000 - "Although inhibitors of angiotensin-converting enzyme (ACE) have improved the treatment of chronic heart failure (CHF), mortality related to this disorder remains unacceptably high" 08/01/1996 - "A randomized, 48-week, double-blind study was performed to investigate the safety and efficacy of 'high' in comparison to continued 'low' angiotensin converting enzyme inhibitor therapy in severe heart failure" Order ALL the reference details at left...
3.	carvedilol (Coreg)FDA LinkGeneric 06/01/2002 - "This suggests that carvedilol therapy for patients with severe chronic heart failure is not only safe and effective but is highly cost effective in the Irish healthcare setting." 04/01/1996 - "The Australia and New Zealand carvedilol heart failure study is the largest completed study of beta-blocker treatment in patients with heart failure of ischaemic aetiology, including 415 patients randomized to carvedilol or placebo and indicating excellent tolerability of a titrated dose regimen and improved ventricular function after 6 months of treatment" 10/16/2007 - "One drug, carvedilol, a nonsubtype-selective betaAR antagonist, has proven particularly effective in the treatment of heart failure, although the mechanism(s) responsible for this are controversial" 09/01/2007 - "Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure." 12/01/2003 - "CONCLUSIONS: The total carvedilol dose was confirmed to be one of the determinants for improvement in heart failure, and it was suggested that the initial serum level also plays an important role in therapeutic outcome" Order ALL the reference details at left...
4.	DiureticsIBA 03/01/2000 - "In addition to their clinical benefits, diuretics are the most cost-effective treatment of any single drug group currently available for the treatment of patients with congestive heart failure." 06/01/2002 - "Heart failure was treated successfully with digitalis and diuretics" 01/01/1987 - "Diuretics bring about a considerable clinical improvement in patients with chronic heart failure but they stimulate the renin-angiotensin system" 05/01/2006 - "Ultrafiltration produced a greater weight and fluid loss than intravenous diuretics in heart failure patients with volume overload in the UNLOAD study but did not exert a greater improvement in breathlessness; however, ultrafiltration did reduce readmission rates" 11/17/1994 - "For over 25 years diuretics have provided the mainstay of treatment for patients with heart failure" Order ALL the reference details at left...
5.	Digoxin (Digitek)FDA LinkGeneric 03/09/2004 - "Digoxin, which is one of the most commonly prescribed drugs for the treatment of heart failure, is mainly eliminated from the circulation by the kidney" 04/01/1989 - "Thus, digoxin therapy is associated with a significant improvement in exercise capacity in patients with chronic heart failure, most likely due to an improved matching of ventilation to perfusion." 11/15/2008 - "Previous trials have shown that digoxin was beneficial in patients with heart failure (HF)" 04/01/1977 - "A study was undertaken to (1) develop an individualized audiovisual patient education program about digoxin and congestive heart failure, and (2) ascertain whether a patient who received the education program from a pharmacist would demonstrate a significantly greater gain in knowledge about digoxin and congestive heart failure than a traditionally-educated patient" 11/01/1987 - "Digoxin therapy results in rapid improvement in cardiac function during acute cardiac failure in patients with and without AMI." Order ALL the reference details at left...
6.	Captopril (Capoten)FDA LinkGeneric 08/01/1996 - "RESULTS: The use of captopril showed important improvement in exercise capacity in patients with heart failure" 12/01/1985 - "In some of the patients with chronic heart failure, captopril (6.25 mg) induced a marked decrease of the arterial blood pressure" 11/01/1997 - "RESULTS: Captopril was associated with a non-significant reduction in 4-week mortality (9.12% vs 9.74%; P = 0.20); but incidence of heart failure was significantly reduced among captopril group (17.0% vs 18.7%; P = 0.01)" 04/05/1993 - "Captopril greatly contributes to the successful therapy of the chronic severe heart failure." 03/01/1993 - "A short period of treatment with intravenous captopril may produce a rapid symptomatic improvement in patients with acute or severe heart failure" Order ALL the reference details at left...
7.	Brain Natriuretic Peptide (Natrecor)FDA Link 02/01/2003 - "The results of several recent clinical trials have shown that administration of nesiritide is safe and highly effective for the initial treatment of patients with acutely decompensated heart failure and can help physicians and nurses meet treatment goals for the management of patients with this serious condition." 11/01/2004 - "Nesiritide has proven to be an effective new treatment for patients with decompensated heart failure." 03/01/2004 - "Nesiritide is a newer neurohormonal agent with proven efficacy and safety for use in decompensated heart failure, but appropriate patient selection has been challenging for clinicians" 05/01/2005 - "Strong evidence exists for use of brain natriuretic peptide in the diagnosis of acute heart failure and for improved clinical outcomes with a brain natriuretic peptide-guided approach to heart failure care" 12/01/2004 - "AIMS: Whether plasma N-terminal brain natriuretic peptide (N-BNP) is useful in the diagnosis of heart failure (HF) depends traditionally on whether it is as good as the putative 'gold-standard', left ventricular ejection fraction (LVEF), in indicating cardiac dysfunction" Order ALL the reference details at left...
8.	Enalapril FDA LinkGeneric 04/01/1983 - "In conclusion, the long-acting converting enzyme inhibitor, enalapril, was effective in patients with chronic congestive heart failure; however, additional studies will be necessary to further delineate the optimal dose range and identify those patients who are most likely to respond to the drug." 05/03/2001 - "Despite similar doses of drug in the two groups, enalapril therapy, as compared with placebo, was associated with a 44 percent reduction (95 percent confidence interval, 27 to 57 percent) in the risk of hospitalization for heart failure among the white patients (P<0.001) but with no significant reduction among black patients (P=0.74)" 12/01/1993 - "The effect of enalapril on mortality and hospitalization for heart failure was significantly greater for patients with the lowest ejection fraction" 07/01/1991 - "The acute efficacy of rapid loading of oral long-acting enalapril in congestive heart failure remains to be established" 07/11/1988 - "There was a significant improvement in New York Heart Association classification in the enalapril group, together with a reduction in heart size and a reduced requirement for other heart failure medication" Order ALL the reference details at left...
9.	Vasodilator Agents (Vasodilators)IBA 01/01/1993 - "Vasodilator agents in chronic heart failure: which is the best option?]" 04/01/1991 - "Potent new inotropic vasodilators have improved ventricular performance but have not prolonged life in patients with end-stage heart failure" 07/01/1977 - "It is apparent that vasodilator treatment can be used effectively in some patients with heart failure with a beneficial haemodynamics response, and that vasodilator agents are likely to find an important place in the management of such patients" 01/01/1994 - "The purpose of this review is to discuss some of these trials and to describe the answers that they provide to the following questions: Are vasodilators beneficial in the treatment of severe heart failure" 09/01/1994 - "On the surface, progress in development of vasodilators and inotropic agents for heart failure has been successful, but the average improved survival time is only about 9 to 18 months" Order ALL the reference details at left...
10.	Spironolactone (Aldactone)FDA LinkGeneric 04/01/2003 - "CONCLUSION: This economic evaluation suggests that the addition of spironolactone to standard therapy for patients with severe chronic heart failure is not only safe and effective, but is highly cost-effective in the Irish healthcare setting." 06/19/1990 - "Although many new drugs useful in the treatment of congestive heart failure have been introduced during the past 25 years, spironolactone continues to have an important role in the management of this condition" 08/01/2004 - "BACKGROUND: Treatment with spironolactone (SPL) is beneficial in patients with severe congestive heart failure (CHF)" 08/01/2002 - "Although the additional therapies with beta-blockers and spironolactone have recently proved to be significantly beneficial for the treatment of advanced heart failure, in the end stages of this disease the prognosis remains quite poor" 09/02/1999 - "In addition, patients who received spironolactone had a significant improvement in the symptoms of heart failure, as assessed on the basis of the New York Heart Association functional class (P<0.001)" Order ALL the reference details at left...

Therapies and Procedures

1.	Heart Transplantation (Grafting, Heart) 03/16/2007 - "Cardiac transplantation is the most effective treatment for advanced heart failure" 01/01/2007 - "At present the most effective cure for end-stage congestive heart failure is cardiac transplantation" 02/01/2005 - "LVAD as bridge to heart transplantation is safe and highly beneficial for terminal heart failure patients with severe PH." 12/01/2003 - "Heart transplantation remains the best treatment option for end-stage heart failure" 10/01/2003 - "BACKGROUND: Heart transplantation is the most effective treatment for well-selected patients with endstage heart failure" Order ALL the reference details at left...
2.	Transplantation (Transplant Recipients) 01/01/2007 - "The HeartMate VE LVAS dramatically improved the functional status and quality of life of these three patients with end-stage heart failure, and all were successfully bridged to transplantation after 659, 995, and 1055 days of support on the device" 11/01/2007 - "BACKGROUND: Left ventricular assist device (LVAD) implantation has proven effective as a bridge to transplantation in end-stage heart failure patients (ESHFPs), although survival during device support is critical" 07/04/2006 - "Optimal medical therapy is superior to transplantation for the treatment of class I, II, and III heart failure: a decision analytic approach." 01/01/2002 - "By combining operative techniques with optimal medical management of heart failure, good outcome can avoid or postpone transplantation" 03/01/2000 - "When these operative techniques that alter the shape of the left ventricle are utilized, in combination with optimal medical management for heart failure, survival is improved and patients can avoid or postpone transplantation." Order ALL the reference details at left...
3.	Drug Therapy (Chemotherapy) 08/01/2005 - "Most of the major trials of pharmacotherapy for the management of chronic heart failure have failed to include significant numbers of African-American patients" 03/10/2007 - "When CSR persists despite optimal drug therapy for heart failure, non-invasive ventilation, particularly as adaptive servoventilation, and cardiac resynchronisation therapy are currently the most promising treatment options." 12/01/2001 - "There is convincing evidence in the literature that tailored drug therapy can be highly effective in preventing heart failure progression as well as in reducing total and sudden mortality" 02/01/2005 - "Chemotherapy induced complete remission, and her heart failure markedly improved" 11/01/1995 - "In continuing of chemotherapy and symptomatic therapy for heart failure patients status gradually improved and complete remission of the myeloma and normalisation of cardiac parameters was achieved" Order ALL the reference details at left...
4.	Transplants (Transplant) 08/01/2004 - "Heart transplants are a proven effective therapy for selected patients with end-stage congestive heart failure" 04/01/1978 - "A simple comparison showed the patients with IMA grafts did better in all four categories; however, in a subsequent analysis in which maldistributed factors were removed, the rates of anginal relief and congestive heart failure were not significantly improved" 08/01/1996 - "CONCLUSIONS: End-stage heart failure patients had improved quality of life from before to 1 year after heart transplant due to less total symptom distress, better health perception, better overall functional status, more overall satisfaction with life, and improved overall quality of life" 03/01/1976 - "This fact can be shown by the poor ventricular function with an elevated left ventricular enddiastolic pressure (LVEDP) of more than 18 mm Hg. The results in patients with congestive heart failure could not be improved by multiple bypass-grafts" 08/01/2004 - "BACKGROUND: B-natriuretic peptide (BNP) is effective in the treatment of decompensated heart failure, but has not specifically been evaluated in the immediate postoperative cardiac transplant population" Order ALL the reference details at left...
5.	Counterpulsation (External Counterpulsation) 06/10/1982 - "IABP was most effective when the ischemic damage of the left ventricle was limited and counterpulsation was instituted before significant heart failure developed" 10/01/2002 - "CONCLUSIONS: Dynamic, biologic, chronic counterpulsation of the aorta using a latissimus dorsi flap (dynamic aortomyoplasty) in selected patients with severe heart failure significantly improved hemodynamic parameters, heart functional data, and clinical functional class" 10/01/2002 - "Juxta-aortic balloon pump counterpulsation in acute experimental heart failure resulted in a significant improvement of hemodynamic parameters: increase of cardiac output (from 0.86 +/- 0.04 to 1.29 +/- 0.09 L/min, p < 0.05) and cardiac index (from 0.03 +/- 0.01 to 0.04 +/- 0.01 L/min per kg, p < 0.05), and decrease of systemic vascular resistance (from 89.76 +/- 6.69 to 66.56 +/- 6.02 mm Hg/L per min, p < 0.05)" 04/01/1999 - "RESULTS: Thoracic and abdominal aortic counterpulsation in heart failure resulted in a significant improvement of hemodynamic parameters" 12/01/1997 - "CONCLUSIONS: In a model of right heart failure, the institution of intraaortic balloon counterpulsation caused a significant improvement in cardiac function" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Heart Failure

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2626 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>